The biology of the human body is complex; developing even one drug to treat illness or disease can take decades and cost over a billion dollars. But Artificial Intelligence is helping to revolutionize the process as Emma Keeling finds out in her meeting with Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine. The biotech company has automated the drug development pipeline - from identifying protein targets to designing new molecules to reach the targets and then also helping speed up clinical trial phases. So far the company has identified 31 potential drugs and one of these is the first drug designed by generative AI to reach human clinical trials.
Additional Footage credit: Insilico Medicine